11h-pyrido(2,1-b)quinazolin-11-one profile

11H-pyrido(2,1-b)quinazolin-11-one: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	68478
CHEMBL ID	1502567
SCHEMBL ID	2427657
MeSH ID	M0115365

Synonym
MLS000728886
11h-pyrido[2,1-b]quinazolin-11-one
smr000307164
OPREA1_644487 ,
SR-01000631645-1
HMS1666I20
pyrido[2,1-b]quinazolin-11-one
578-96-1
inchi=1/c12h8n2o/c15-12-9-5-1-2-6-10(9)13-11-7-3-4-8-14(11)12/h1-8h
monjtouxcwkofs-uhfffaoysa-
AKOS005617642
NCGC00245900-01
STK773681
HMS2705F06
11h-pyrido(2,1-b)quinazolin-11-one
11-pq
CCG-41580
CHEMBL1502567
SCHEMBL2427657
AE-641/00636037
DTXSID50206494
pyrido[2,1-b]quinazolin-10-one
CS-0326940

Protein Targets (15)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, 2-oxoglutarate Oxygenase	Homo sapiens (human)	Potency	28.1838	0.1778	14.3909	39.8107	AID2147
Chain A, Ferritin light chain	Equus caballus (horse)	Potency	28.1838	5.6234	17.2929	31.6228	AID485281
acid sphingomyelinase	Homo sapiens (human)	Potency	25.1189	14.1254	24.0613	39.8107	AID504937
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	31.6228	0.1000	20.8793	79.4328	AID588456
BRCA1	Homo sapiens (human)	Potency	11.2202	0.8913	7.7225	25.1189	AID624202
ATAD5 protein, partial	Homo sapiens (human)	Potency	20.5878	0.0041	10.8903	31.5287	AID504466; AID504467
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	31.6228	0.0112	12.4002	100.0000	AID1030
alpha-galactosidase	Homo sapiens (human)	Potency	35.4813	4.4668	18.3916	35.4813	AID2107
lysosomal alpha-glucosidase preproprotein	Homo sapiens (human)	Potency	31.6228	0.0366	19.6376	50.1187	AID1466; AID2242
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	20.5962	0.0041	9.9848	25.9290	AID504444
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	89.1251	0.0501	27.0736	89.1251	AID588590
survival motor neuron protein isoform d	Homo sapiens (human)	Potency	14.1254	0.1259	12.2344	35.4813	AID1458
muscleblind-like protein 1 isoform 1	Homo sapiens (human)	Potency	17.7828	0.0041	9.9625	28.1838	AID2675
Neuronal acetylcholine receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	31.6228	3.5481	18.0395	35.4813	AID1466
Neuronal acetylcholine receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	31.6228	3.5481	18.0395	35.4813	AID1466
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (29)

Assay ID	Title	Year	Journal	Article
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1362733	Cytotoxicity against rat CC1 cells assessed as cell survival at 50 ug/ml after 24 hrs by Alamar blue reduction assay relative to control	2018	Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17	Efflux pump inhibition by 11H-pyrido[2,1-b]quinazolin-11-one analogues in mycobacteria.
AID1362731	Cytotoxicity against rat CC1 cells assessed as decrease in cell survival at 200 ug/ml after 24 hrs by Alamar blue reduction assay relative to control	2018	Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17	Efflux pump inhibition by 11H-pyrido[2,1-b]quinazolin-11-one analogues in mycobacteria.
AID1362735	Inhibition of LfrA in Mycobacterium smegmatis MC2 155 ATCC 700084 assessed as increase in EtBr accumulation at 50 ug/ml measured every 5 mins for 35 mins by fluorometric analysis	2018	Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17	Efflux pump inhibition by 11H-pyrido[2,1-b]quinazolin-11-one analogues in mycobacteria.
AID1362716	Inhibition of LfrA in Mycobacterium smegmatis MC2 155 ATCC 700084 assessed as decrease in EtBr MIC at 100 ug/ml after 72 hrs by MTT assay relative to control	2018	Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17	Efflux pump inhibition by 11H-pyrido[2,1-b]quinazolin-11-one analogues in mycobacteria.
AID1362725	Inhibition of LfrA in Mycobacterium smegmatis MC2 155 ATCC 700084 assessed as potentiation of EtBr-induced bactericidal activity at 100 ug/ml after 24 hrs	2018	Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17	Efflux pump inhibition by 11H-pyrido[2,1-b]quinazolin-11-one analogues in mycobacteria.
AID638469	Inhibition of His-tagged recombinant human IDO1 expressed in Escherichia coli using tryptophan as substrate at 200 uM by spectrophotometric analysis	2012	Bioorganic & medicinal chemistry, Feb-01, Volume: 20, Issue:3	Novel indoleamine 2,3-dioxygenase-1 inhibitors from a multistep in silico screen.
AID1362713	Growth inhibition of Mycobacterium smegmatis MC2 155 ATCC 700084 after 72 hrs by MTT assay	2018	Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17	Efflux pump inhibition by 11H-pyrido[2,1-b]quinazolin-11-one analogues in mycobacteria.
AID1362721	Inhibition of LfrA in Mycobacterium smegmatis MC2 155 ATCC 700084 assessed as decrease in norfloxacin MIC at 25 ug/ml after 72 hrs by MTT assay relative to control	2018	Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17	Efflux pump inhibition by 11H-pyrido[2,1-b]quinazolin-11-one analogues in mycobacteria.
AID1362738	Inhibition of LfrA in Mycobacterium smegmatis MC2 155 ATCC 700084 assessed as increase in norfloxacin accumulation at 25 ug/ml measured every 5 mins for 35 mins by fluorometric analysis	2018	Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17	Efflux pump inhibition by 11H-pyrido[2,1-b]quinazolin-11-one analogues in mycobacteria.
AID1362712	Inhibition of LfrA in Mycobacterium smegmatis MC2 155 ATCC 700084 assessed as potentiation of norfloxacin-induced bactericidal activity at 25 ug/ml after 24 to 48 hrs	2018	Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17	Efflux pump inhibition by 11H-pyrido[2,1-b]quinazolin-11-one analogues in mycobacteria.
AID1362732	Cytotoxicity against rat CC1 cells assessed as cell survival at 100 ug/ml after 24 hrs by Alamar blue reduction assay relative to control	2018	Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17	Efflux pump inhibition by 11H-pyrido[2,1-b]quinazolin-11-one analogues in mycobacteria.
AID1362728	Inhibition of LfrA in Mycobacterium smegmatis MC2 155 ATCC 700084 assessed as potentiation of EtBr-induced bactericidal activity at 100 ug/ml after 48 hrs	2018	Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17	Efflux pump inhibition by 11H-pyrido[2,1-b]quinazolin-11-one analogues in mycobacteria.
AID1362734	Inhibition of LfrA in Mycobacterium smegmatis MC2 155 ATCC 700084 assessed as increase in EtBr accumulation at 25 ug/ml measured every 5 mins for 35 mins by fluorometric analysis	2018	Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17	Efflux pump inhibition by 11H-pyrido[2,1-b]quinazolin-11-one analogues in mycobacteria.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (9.09)	29.6817
2010's	9 (81.82)	24.3611
2020's	1 (9.09)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	12 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	2.17	1	aromatic ether; nitrile; polyether; tertiary amino compound
carbonyl cyanide m-chlorophenyl hydrazone Carbonyl Cyanide m-Chlorophenyl Hydrazone: A proton ionophore. It is commonly used as an uncoupling agent and inhibitor of photosynthesis because of its effects on mitochondrial and chloroplast membranes.. CCCP : A member of the class of monochlorobenzenes that is benzene substituted by 2-(1,3-dinitrilopropan-2-ylidene)hydrazinyl and chloro groups at positions 1 and 3, respectively. It is a mitochondrial depolarizing agent that induces reactive oxygen species mediated cell death.	2.17	1	hydrazone; monochlorobenzenes; nitrile	antibacterial agent; geroprotector; ionophore
s-methylisothiopseudouronium S-methylisothiopseudouronium: inhibits nitric oxide synthase; structure in first source	2.07	1
3-hydroxy-2-naphthoic acid 3-hydroxy-2-naphthoic acid: RN given refers to parent cpd	2.07	1	naphthoic acid
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	2.21	1	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
norharman norharman: RN given refers to parent cpd. beta-carboline : The parent compound of the beta-carbolines, a tricyclic structure comprising an indole ring system ortho- fused to C-3 and C-4 of a pyridine ring.	2.07	1	beta-carbolines; mancude organic heterotricyclic parent	fungal metabolite; marine metabolite
harmol harmol: harmol is oxidized form of alkaloid harmolol; RN given refers to parent cpd; structure	2.07	1	harmala alkaloid
idph-791 [no description available]	2.07	1
1-methyltryptophan 1-methyltryptophan: an immunomodulator. 1-methyltryptophan : A tryptophan derivative that is tryptophan carrying a single methyl substituent at position 1 on the indole.	2.07	1	indolyl carboxylic acid

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Encephalitis, Polio [description not available]	2.06	1
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	2.06	1
Anemia, Fanconi [description not available]	2.13	1
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	2.13	1

11h-pyrido(2,1-b)quinazolin-11-one

Description

Cross-References

Synonyms (23)

Protein Targets (15)

Potency Measurements

Bioassays (29)

Research

Studies (11)

Market Indicators

Research Demand Index: 11.94

Study Types

11h-pyrido(2,1-b)quinazolin-11-one

Description

Cross-References

Synonyms (23)

Protein Targets (15)

Potency Measurements

Bioassays (29)

Research

Studies (11)

Market Indicators

Research Demand Index: 11.94

Study Types

Related Drugs (9)

Related Conditions (6)